Literature DB >> 8776593

Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors.

I Hatada1, J Inazawa, T Abe, M Nakayama, Y Kaneko, Y Jinno, N Niikawa, H Ohashi, Y Fukushima, K Iida, C Yutani, S Takahashi, Y Chiba, S Ohishi, T Mukai.   

Abstract

p57KIP2 is a potent tight-binding inhibitor of several G1 cyclin complexes, and is a negative regulator of cell proliferation. The gene encoding human p57KIP2 is located on chromosome 11p15.5, a region implicated in both sporadic cancers and Beckwith-Wiedemann syndrome (BWS), a cancer syndrome, making it a tumor suppressor candidate. Several types of childhood tumors including Wilms' tumor, adrenocortical carcinoma and rhabdomyosarcoma display a specific loss of maternal 11p15 alleles, suggesting that genomic imprinting plays an important part. Genetic analysis of the familial BWS has indicated maternal carriers and suggested a role in genomic imprinting. Previously, we demonstrated that p57KIP2 is imprinted in the mouse. Here we describe the genomic imprinting of human p57KIP2 and the reduction of its expression in Wilms' tumors. High resolution mapping locates p57KIP2 in the region responsible for both tumor suppressivity and BWS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8776593     DOI: 10.1093/hmg/5.6.783

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  37 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

Authors:  W Hartmann; A Waha; A Koch; C G Goodyer; S Albrecht; D von Schweinitz; T Pietsch
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Low and maternal-specific expression of p57KIP2 in hydatidiform mole and its clinical implication.

Authors:  Yali Xiong; Yang Cao; Hongfa Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

4.  Autonomous silencing of the imprinted Cdkn1c gene in stem cells.

Authors:  Michelle D Wood; Hitoshi Hiura; Simon J Tunster; Takahiro Arima; Jong-Yeon Shin; Michael J Higgins; Rosalind M John
Journal:  Epigenetics       Date:  2010-04-01       Impact factor: 4.528

Review 5.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

6.  Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors.

Authors:  D O'Keefe; D Dao; L Zhao; R Sanderson; D Warburton; L Weiss; K Anyane-Yeboa; B Tycko
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

Review 7.  Pancreatic β-cell KATP channels: Hypoglycaemia and hyperglycaemia.

Authors:  Kate Bennett; Chela James; Khalid Hussain
Journal:  Rev Endocr Metab Disord       Date:  2010-09       Impact factor: 6.514

8.  Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.

Authors:  Ke-Jun Nan; Hui Guo; Zhi-Ping Ruan; Zhao Jing; Shaan-Xi Liu
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

9.  Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome.

Authors:  N Diaz-Meyer; Y Yang; S N Sait; E R Maher; M J Higgins
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

10.  CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.

Authors:  Ruiying Zhao; Heng-Yin Yang; Jihyun Shin; Liem Phan; Lekun Fang; Ting-Fang Che; Chun-Hui Su; Sai-Ching J Yeung; Mong-Hong Lee
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.